Lead long-acting injectable assets

About DelSiTech

DelSiTech is a private, pre-revenue Finnish biotech leveraging its proprietary Silica Matrix platform to develop long-acting injectable formulations. The company's versatile technology enables controlled drug release over days to months, targeting improved patient adherence in metabolic disease and pain. Its business model combines internal pipeline development with technology licensing partnerships, positioning it as a potential enabler for next-generation sustained-release therapies.

Therapeutic Areas